ストックスクリーナーアプリを入手
2.84
0.71%
0.02
アフターアワーズ：
2.85
0.01
+0.35%
Editas Medicine Inc (EDIT) 最新ニュース
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Editas Medicine Inc (EDIT) Stock Price, Trades & News - GuruFocus
Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership - Stock Titan
Editas Medicine (EDIT) Institutional Ownership 2026 $EDIT - MarketBeat
Editas Medicine, Inc. (EDIT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Editas Medicine (EDIT) Short Interest & Short Float | Updated Aug 2026 $EDIT - MarketBeat
Editas Medicine (EDIT) Slips to $2.81 as Gene-Editing Stock Nears Critical SupportSchiff Line - dars.gov.et
Editas Medicine, Inc. (EDIT) stock price, news, quote and history - Yahoo Finance Singapore
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Editas Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Weekly Recap: Editas Medicine, Inc. Q2 results and EDIT-401 Australia CTN - TradingView
Editas Medicine Inc (EDIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
HC Wainwright Boosts Earnings Estimates for Editas Medicine - MarketBeat
Editas Medicine, Inc. (0IFK.L) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold - MarketBeat
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating - Moomoo
H.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000 - Stock Titan
Editas Medicine, Inc. (EDIT) director reports no share or option holdings - Stock Titan
Editas Medicine, Inc. expected to post a loss of 27 cents a shareEarnings Preview - TradingView
Editas Medicine, Inc. (0IFK.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4 - Moomoo
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus - Yahoo Finance
Editas Medicine Q2 Operating Expenses USD 30. - Moomoo
Editas Medicine (NASDAQ:EDIT) Issues Earnings Results - marketbeat.com
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Editas: Q2 Earnings Snapshot - marketscreener.com
Editas Medicine Q2 net loss narrows and beats estimates - TradingView
Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary - TradingView
Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan - Stock Titan
Editas Medicine Announces Second Quarter 2026 Results and Business Updates - The Manila Times
EDIT: EDIT-401 advances toward clinical trials with robust preclinical data and improved financials - TradingView
Editas Medicine (Nasdaq: EDIT) equity deal lifts cash to $211.6M - Stock Titan
BRIEF-Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million - TradingView
Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates - Moomoo
Editas Medicine earnings beat by $0.12, revenue topped estimates - Investing.com Canada
Editas Medicine appoints Patrick Ellinor to board of directors By Investing.com - Investing.com UK
Editas Medicine appoints Patrick Ellinor to board of directors - Investing.com
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. - The Manila Times
Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Editas Medicine (EDIT) Climbs 4.5% to $2.77 as Support HoldsHedge Fund Favorites - dars.gov.et
Renaissance Technologies LLC Raises Position in Editas Medicine, Inc. $EDIT - MarketBeat
Form 4 Editas Medicine For: 30 July By Investing.com - Investing.com South Africa
Editas Medicine EVP, chief scientific officer, sells $13,157 in stock By Investing.com - Investing.com Nigeria
Editas Medicine (NASDAQ:EDIT) EVP Linda Burkly Sells 4,928 Shares of Stock - MarketBeat
EDIT|Editas Medicine Inc|Price:2.680|Chg%:+0.080 - TradingKey
Editas Medicine Inc (EDIT) Cash Flow - TradingKey
Editas Medicine Inc (EDIT) Income Statement - TradingKey
Editas Medicine Inc (EDIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Editas Medicine Inc (EDIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Editas Medicine Inc (EDIT) Balance Sheet - TradingKey
Editas Medicine, Inc. Revenue Breakdown – NASDAQ:EDIT - TradingView
Editas Medicine Q1 2026 Earnings: Narrower-than-expected loss as gene editing pipeline progressesFinancial Summary - dars.gov.et
Editas Medicine (EDIT) Dips 4.76% as Shares Approach Key Support LevelHedge Fund Exposure - dars.gov.et
Editas Medicine Slips 2.34% as Gene Editing Stock Tests Key Support at $2.57Fear Greed Extreme - dars.gov.et
Form 144 Editas Medicine For: 22 July By Investing.com - Investing.com Nigeria
Editas Medicine stock trades steady as gene-editing pipeline advances and cash runway extends - Ad-hoc-news.de
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):